Simcere Zaiming has entered a collaboration deal with Shenzhen TargetRx to bring the third-generation anaplastic lymphoma ...

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration ...

EpimAb Biotherapeutics sold global (ex-China) rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in ...

Simcere Zaiming has entered a collaboration deal with Shenzhen TargetRx to bring the third-generation anaplastic lymphoma kinase (ALK) inhibitor, TGRX-326, to the Chinese market. Simcere Zaiming ...

Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group, announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual ...

NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement ...